The pharmaceutical industry constantly seeks high-quality intermediates to ensure the efficacy and safety of medications. Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate, identified by CAS number 769195-26-8, stands out as a pivotal compound, particularly in the synthesis of Sitagliptin. Sitagliptin is a widely prescribed dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage type 2 diabetes mellitus. The precise molecular structure of Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate, featuring a trifluorophenyl group, is instrumental in conferring the desired pharmacological properties to Sitagliptin.

As a leading Sitagliptin intermediate manufacturer in China, NINGBO INNO PHARMCHEM CO.,LTD. understands the critical importance of purity and consistency for this compound. The Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate price can vary, but investing in a high-purity product is paramount for successful API synthesis. Our commitment is to provide pharmaceutical companies with a reliable source for this essential chemical intermediate, ensuring compliance with stringent quality standards.

The synthesis of Sitagliptin involves complex chemical transformations, and Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate serves as a foundational building block. Its chemical properties, including its appearance as a pale yellow to light yellow solid, and its reactivity profile, are well-characterized, enabling efficient incorporation into the Sitagliptin manufacturing process. We emphasize the importance of sourcing such intermediates from trusted suppliers who can offer comprehensive technical support and Certificates of Analysis.

For companies looking to buy Methyl 3-Oxo-4-(2,4,5-trifluorophenyl)butanoate, partnering with a manufacturer that prioritizes research and development, such as NINGBO INNO PHARMCHEM CO.,LTD., ensures access to both quality materials and valuable process insights. Exploring the specific CAS 769195-26-8 properties can guide your formulation and production strategies effectively. By securing a consistent supply of this crucial intermediate, pharmaceutical businesses can streamline their production, enhance product quality, and ultimately contribute to better patient outcomes in diabetes management.